GSK Enters Exclusive Collaboration With SBP Group, a Market Leader in Hepatology in China, to Accelerate Bepirovirsen at Launch
May 12, 2026
May 12, 2026
LONDON, England, May 12 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on ay 11, 2026:
* * *
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
* Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China
* Chronic hepatitis B affects 75 million people in Chi . . .
* * *
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
* Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China
* Chronic hepatitis B affects 75 million people in Chi . . .